查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863405

大腸癌篩檢和診斷市場按類型、產品、應用和最終用戶分類 - 全球預測 2025-2032

Colorectal Cancer Screening & Diagnostic Market by Type, Product, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，大腸癌篩檢和診斷市場將成長至 33.5 億美元，複合年成長率為 7.60%。

主要市場統計數據
基準年 2024 18.6億美元
預計年份：2025年 19.9億美元
預測年份：2032年 33.5億美元
複合年成長率 (%) 7.60%

簡明扼要而又全面地概述了影響大腸癌篩檢和診斷的臨床、經濟和營運因素。

大腸癌仍然是癌症發病率和死亡率的主要原因之一，隨著臨床醫生、支付方和患者尋求更便利、更準確、更經濟有效的篩檢和診斷方法，篩檢和診斷格局正在迅速變化。過去十年，非侵入性檢測、影像學和分子診斷技術的進步使臨床管道更加多元化，而公共衛生政策也加強了提高高風險族群篩檢率的力度。因此，該領域的相關人員不再局限於傳統的胃腸病學家，而是擴展到包括基層醫療提供者、診斷實驗室、門診手術中心以及專注於數位醫療和遠端病人參與的供應商在內的更廣泛的群體。

變革性轉變正在重塑結直腸癌篩檢的臨床實踐、技術應用和病患管道

過去幾年，我們觀察到多項因素共同作用，重塑了大腸直腸癌的篩檢和診斷實踐。首先，病患的偏好和醫療系統容量的限制，促使人們更加關注非侵入性的居家篩檢方法，進而減少對醫療機構的依賴。同時，糞便檢驗和分子血液檢測技術的進步，旨在平衡檢測的可及性和診斷性能，進一步推動了這一轉變。其次，影像和內視鏡平台的性能和舒適度不斷提升。雖然大腸鏡檢查仍然是診斷的黃金標準，但CT結腸成像和增強型內視鏡成像技術正擴大用於風險分層和作為替代診斷方案。

2025年美國關稅變化對供應鏈、採購和臨床營運的累積影響

新訂定的關稅和不斷變化的貿易政策對結直腸癌篩檢和診斷領域的相關人員有重大影響。進口關稅的變化可能會增加CT掃描儀、內視鏡等設備以及試劑盒、試劑等耗材的到岸成本，從而影響醫院、門診手術中心和診斷實驗室的採購時間和資本支出決策。為此，醫療服務提供者和經銷商可能會推遲一些非緊急採購，優先採購可更換的耗材，或重新與供應商談判合約以維持營運預算。

關鍵細分洞察突顯了測試方法效能、產品定位、適應症匹配度和最終用戶需求促進因素。

按檢測觀點分析市場，揭示了篩檢和糞便檢驗之間微妙的共生關係。篩檢檢測包括血液檢測和影像檢查，後者包括大腸鏡檢查、CT結腸成像和乙狀結腸鏡檢查。在此框架下，大腸鏡檢查仍是確診和治療性介入的主要手段。同時，CT結腸成像提供了一種創傷性較小的影像學檢查方法，尤其適用於不願接受傳統大腸鏡檢查的患者。乙狀結腸鏡檢查在人群篩檢中的重要性有所下降，但在某些臨床情況和監測通訊協定中仍然有用。血液檢測正逐漸成為風險分層的輔助手段，並且與檢驗的預後標記結合使用時，可能會影響疾病的臨床表現。

區域洞察突顯全球市場中不同的採用模式、法規環境和產能限制

區域趨勢對篩檢和診斷策略的實施方式有顯著影響。在美洲，完善的篩檢計畫、健全的檢查室基礎設施以及重視預防性醫療的支付方環境，促進了糞便檢驗和大腸鏡檢查的廣泛應用；同時，私部門的創新也在加速更複雜的分子檢測技術的普及。另一方面，歐洲、中東和非洲的情況則截然不同，既有的公共衛生篩檢策略與資源分配不均並存。西方市場強調以指南為導向的篩檢管道和集中式檢測網路，而中東部分地區的醫療能力限制則促使人們優先採用非侵入性、低基礎設施投入的方法來擴大篩檢涵蓋範圍。

為領先組織提供定義產品策略、合作模式和創新管道的競爭考察和商業洞察

在競爭激烈的市場環境中，成熟的醫療設備和診斷公司正採取互補策略，將產品創新與聯盟建立結合。一些公司專注於改進設備平台和內視鏡的人體工學設計，以提升臨床療效和手術效率。另一些公司則優先開發高靈敏度耗材，例如先進試劑和糞便DNA檢測，以擴大非侵入性篩檢的覆蓋範圍。此外，一些專業實驗室和診斷Start-Ups公司正在研發新型分子檢測和血液檢測方法，以整合到現有的臨床工作流程中，並提供可擴展的檢測解決方案。

為行業領導者提供切實可行的建議，以加快技術應用、管理風險並使產品和服務與醫療保健優先事項保持一致。

產業領導者應優先考慮組合式策略，在投資高影響力設備的同時，兼顧可擴展的耗材解決方案，以實現廣泛應用。透過強調模組化產品設計和靈活的服務協議，製造商可以減少醫院和門診手術中心的採購摩擦，同時提高檢查室的吞吐量。同時，產生以患者療效、成本效益和實際效用為重點的臨床證據，可以增強與支付方的談判能力，並支持將其納入實踐指南。與醫保機構和衛生技術評估組織建立早期且持續的對話，也有助於加速醫療覆蓋和推廣應用的進程。

調查方法概述了用於得出此結論的證據綜合、原始研究和檢驗方法。

本分析採用結構化的混合方法證據綜合分析，主要基於對臨床專家、實驗室主任和採購人員的定性訪談，並結合對同行評審的臨床文獻和官方監管文件的系統性回顧。主要研究包括對醫院、門診手術中心、診斷實驗室和研究機構進行深度訪談，以了解其營運限制、採購行為和臨床偏好。二級資訊來源用於將臨床指南、技術趨勢和法規環境置於特定背景下進行解讀，以確保對趨勢的解釋與當代實踐相符。

結論概述了篩檢篩檢下一步工作的策略意義和優先事項。

大腸直腸癌篩檢和診斷格局正朝著以患者為中心、實證醫學為導向、營運整合的醫療模式轉變。非侵入性檢測和耗材服務有助於擴大服務覆蓋範圍，緩解醫療資源緊張，而影像和內視鏡平台則繼續提供關鍵的診斷和治療能力。貿易政策和採購趨勢進一步增加了策略複雜性，凸顯了供應鏈韌性以及在地化生產和分銷模式的重要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧演算法整合到大腸鏡影像中，以提高即時息肉檢測的靈敏度
  • 液態生物檢體檢測在結直腸癌復發非侵入性檢測與監測的臨床應用
  • 多標靶糞便DNA檢測作為一般風險族群篩檢替代方案的市場滲透率不斷提高
  • 利用基因風險分析和新型生物標記組合，擴展個人化篩檢通訊協定
  • 為分散式低資源環境開發攜帶式腸癌篩檢設備
  • 實施基於遠端醫療的病人參與平台，用於遠距結直腸癌篩檢的導航和隨訪
  • 改變報銷框架，擴大公共醫療保健系統中非侵入性大腸直腸癌篩檢的覆蓋範圍
  • 診斷實驗室與數位醫療公司建立策略合作夥伴關係，以整合大腸癌患者數據

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按類型分類的結直腸癌篩檢和診斷市場

  • 篩檢測試
    • 血液檢查
    • 影像檢查
      • 大腸鏡檢查
      • CT結腸成像
      • 軟性乙狀結腸鏡檢查
  • 糞便檢驗
    • 糞便免疫化學檢測
    • 癒創木脂大便潛血試驗
    • 多標靶糞便DNA檢測

9. 按產品分類的大腸直腸癌篩檢和診斷市場

  • 消耗品
    • 成套工具
    • 試劑
  • 裝置
    • CT掃描儀
    • 內視鏡檢查

第10章 按應用分類的大腸直腸癌篩檢和診斷市場

  • 疾病監測
  • 早期檢測
  • 預後評估

第11章 按最終用戶分類的結直腸癌篩檢和診斷市場

  • 門診手術中心
  • 診斷實驗室
  • 醫院
  • 研究所

第12章 各地區大腸癌篩檢與診斷市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按群體分類的大腸直腸癌篩檢和診斷市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國大腸癌篩檢與診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • AbbVie Inc.
    • Agilent Technologies, Inc.
    • Bayer AG
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Bristol-Myers Squibb Company
    • Clinical Genomics Technologies Pty Ltd.
    • Eiken Chemical Co., Ltd.
    • Epigenomics AG
    • Exact Sciences Corp.
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holdings Corporation
    • GE HealthCare Technologies, Inc.
    • Guardant Health, Inc.
    • Hologic, Inc.
    • Illumina, Inc.
    • KARL STORZ SE & Co. KG
    • Medtronic PLC
    • Merck KGaA
    • Myriad Genetics, Inc.
    • Novartis AG
    • Novigenix SA
    • Olympus Corporation
    • Prenetics Global Limited
    • QIAGEN NV
    • Quest Diagnostics Incorporated
    • Sanofi SA
    • Siemens AG
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AF41

The Colorectal Cancer Screening & Diagnostic Market is projected to grow by USD 3.35 billion at a CAGR of 7.60% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.86 billion
Estimated Year [2025] USD 1.99 billion
Forecast Year [2032] USD 3.35 billion
CAGR (%) 7.60%

A concise but comprehensive overview of the evolving clinical, economic, and operational forces transforming colorectal cancer screening and diagnostics

Colorectal cancer remains a leading cause of cancer morbidity and mortality, and the screening and diagnostic landscape is evolving rapidly as clinicians, payers, and patients seek more accessible, accurate, and cost-effective approaches. Over the past decade, advances in noninvasive testing, imaging modalities, and molecular diagnostics have diversified clinical pathways, while public health initiatives have intensified efforts to increase screening uptake among at-risk populations. As a result, the ecosystem now includes a broader range of stakeholders beyond traditional gastrointestinal specialists, encompassing primary care providers, diagnostics laboratories, ambulatory surgical centers, and technology vendors focused on digital health and remote patient engagement.

Clinical practice guidelines continue to emphasize early detection and risk-appropriate screening, and this has spurred investment in technologies that reduce barriers to participation. Simultaneously, the healthcare delivery context has placed renewed emphasis on patient experience and operational efficiency, prompting providers to adopt stool-based testing and streamlined referral pathways that can reduce the burden on endoscopy suites. Regulatory frameworks and payer policies are adapting to accommodate new evidence, increasing the importance of robust clinical validation and real-world outcomes. Consequently, industry players must navigate a confluence of clinical, economic, and logistical factors to deliver solutions that align with evolving standards of care and stakeholder expectations.

In this environment, a strategic view that integrates the diversity of screening modalities, the segmentation of product types, and the variability of end-user settings is essential for identifying sustainable opportunities. The following sections examine the transformative shifts, regulatory and trade pressures, segmentation dynamics, regional nuances, competitive behavior, and actionable recommendations that together define the contemporary colorectal cancer screening and diagnostics domain.

Transformative shifts reshaping clinical practice, technology adoption, and patient pathways across colorectal cancer screening

The past several years have witnessed multiple converging shifts that are reshaping colorectal cancer screening and diagnostic practice. First, patient preference and system capacity have accelerated interest in noninvasive, home-based screening modalities that reduce dependency on facility-based procedures. This shift is complemented by technological progress in stool-based assays and blood-based molecular tests that aim to balance accessibility with diagnostic performance. Second, imaging and endoscopic platforms continue to improve in capability and comfort, where colonoscopy remains the diagnostic gold standard but CT colonography and enhanced endoscopic imaging are increasingly used for risk stratification and alternative diagnostic algorithms.

Concurrently, payer policies and quality metrics are exerting pressure on screening pathways to deliver measurable population health outcomes, prompting providers to implement organized screening programs and reminder systems. Diagnostics laboratories and instrument manufacturers are responding by enhancing automation, integrating digital reporting, and fostering interoperability with electronic health records to streamline workflows. Additionally, the emergence of precision oncology concepts is driving demand for diagnostics that support early detection, prognosis assessment, and personalized post-diagnostic monitoring. Lastly, cross-sector collaboration among clinical researchers, technology vendors, and health systems has accelerated evidence generation, enabling faster translation of promising assays into routine care. Together, these dynamics create an environment where scalability, demonstrated clinical utility, and operational integration determine which innovations achieve sustained adoption.

Cumulative implications of tariff policy changes in the United States for 2025 on supply chains, procurement, and clinical operations

Emerging tariff measures and trade policy shifts have meaningful implications for stakeholders operating in the colorectal cancer screening and diagnostics space. Changes in import duties can increase the landed cost of instruments such as CT scanners and endoscopes, as well as consumables including kits and reagents, thereby influencing procurement timing and capital expenditure decisions by hospitals, ambulatory surgical centers, and diagnostics laboratories. In response, healthcare providers and distributors may delay nonurgent purchases, prioritize replaceable consumables, or renegotiate supplier contracts to preserve operating budgets.

Moreover, tariffs can amplify supply chain fragility by incentivizing suppliers to reconfigure production footprints, pursue nearshoring, or source alternative component vendors. This reconfiguration can lead to transitional disruptions in availability and lead times. To mitigate these effects, manufacturers often accelerate localization of assembly or partner with domestic suppliers, a process that can introduce short-term cost increases but ultimately enhance resilience. Clinically, any procurement delays or cost pressures may shift the balance toward lower-resource, minimally invasive screening options that maintain throughput while limiting capital strain.

Finally, tariff-driven cost pressures also interact with reimbursement policies and payer negotiations. Health systems and diagnostics providers will need to demonstrate cost-effectiveness and operational value more rigorously when facing higher acquisition costs. As a result, organizations that proactively model scenarios, diversify supply chains, and engage in strategic sourcing partnerships will be better positioned to preserve access to advanced diagnostics while managing the financial implications of evolving trade policy.

Key segmentation insights illuminating modality performance, product positioning, application alignment, and end-user demand drivers

Analyzing the market through the lens of testing type reveals nuanced coexistence between Screening Tests and Stool Tests, where Screening Tests encompass Blood Tests and Imaging Tests, and Imaging Tests include Colonoscopy, CT Colonography, and Flexible Sigmoidoscopy. Within this structure, Colonoscopy retains primacy for definitive diagnosis and therapeutic intervention, while CT Colonography serves as a less invasive imaging alternative particularly attractive to patients averse to traditional colonoscopy. Flexible Sigmoidoscopy has diminished in prominence for population screening, yet it remains relevant in specific clinical contexts and surveillance protocols. Blood Tests are an emerging adjunct for risk stratification and may influence referral patterns when coupled with validated prognostic markers.

From a product perspective, the distinction between Consumables and Instruments shapes adoption dynamics. Consumables, comprising Kits and Reagents, are central to scaling stool-based and molecular testing programs because they support decentralized specimen collection and laboratory automation. Instruments, notably CT Scanners and Endoscopes, represent longer-term capital investments and require coordinated scheduling, maintenance, and clinician training. Consequently, organizations that offer integrated consumable supply and instrument support tend to secure deeper penetration across clinical settings.

Application segmentation-Disease Monitoring, Early Detection, and Prognosis Assessment-highlights how different technologies align with distinct clinical needs. Early Detection remains the principal driver of population screening initiatives, leveraging fecal immunochemical tests and multitarget stool DNA testing to maximize participation, whereas Disease Monitoring and Prognosis Assessment increasingly rely on molecular assays and, in some cases, blood-based biomarkers to manage post-treatment surveillance and personalize follow-up intervals. The end-user landscape composed of Ambulatory Surgical Centers, Diagnostics Laboratories, Hospitals, and Research Institutes further influences product selection; for example, diagnostics laboratories favor high-throughput kits and reagents, hospitals prioritize integrated instrument ecosystems with strong service agreements, ambulatory surgical centers emphasize throughput and patient flow for endoscopic procedures, and research institutes focus on innovative assays and clinical validation for emerging modalities.

Understanding these intersecting segmentation dimensions clarifies where investment and clinical evidence will yield the greatest impact. Products that bridge consumable convenience with robust analytical performance, supported by service models that reduce operational friction for end users across settings, will be best positioned to influence standard practice and sustain adoption.

Regional insights highlighting differentiated adoption patterns, regulatory environments, and capacity constraints across global markets

Regional dynamics exert a powerful influence on how screening and diagnostic strategies are implemented. In the Americas, organized screening programs, strong laboratory infrastructure, and payer environments that reward preventive care have supported broad use of stool-based tests and colonoscopy, while private sector innovation has accelerated adoption of higher-complexity molecular assays. Meanwhile, Europe, the Middle East & Africa presents a heterogeneous landscape where established public health screening initiatives coexist with resource variability; western European markets emphasize guideline-driven screening pathways and centralized laboratory networks, whereas parts of the Middle East & Africa face capacity constraints that favor noninvasive, low-infrastructure approaches for expanding access.

Asia-Pacific exhibits a rapid pace of technology adoption and a growing emphasis on population health initiatives, with several countries investing in endoscopy capacity and molecular diagnostics to address rising cancer burdens associated with demographic shifts. In many markets across this region, digital health solutions and mobile outreach are leveraged to increase screening uptake, and local manufacturing partnerships are increasingly common to support regional supply chains. Across all regions, the interplay between regulatory approvals, reimbursement frameworks, and clinician training determines the speed and scale of adoption. Ultimately, stakeholders seeking to expand presence or deploy new technologies must tailor strategies to regional policy priorities, infrastructure readiness, and cultural factors that influence patient participation in screening programs.

Competitive and corporate insights that define product strategies, collaboration models, and innovation pathways among leading organizations

Across the competitive landscape, established medical device manufacturers and diagnostics companies are pursuing complementary strategies that blend product innovation with alliance building. Some organizations concentrate on refining instrument platforms and endoscope ergonomics to enhance clinical outcomes and procedure efficiency, while others prioritize the development of high-sensitivity consumables such as advanced reagents and stool DNA assays aimed at broadening noninvasive screening uptake. Additionally, a cohort of specialty laboratories and diagnostic startups is advancing novel molecular assays and blood-based approaches designed to integrate with existing clinical workflows and provide scalable testing solutions.

Partnerships between device manufacturers, laboratory networks, and digital health providers have become a common pathway to accelerate market access and clinical validation. These collaborations enable bundled offerings that include test kits, laboratory processing, reporting platforms, and patient outreach tools, thereby addressing key barriers to screening adherence. Mergers and acquisitions remain a strategic lever for companies seeking to secure complementary capabilities, expand geographic reach, or internalize critical supply components. Furthermore, regulatory milestones and the generation of real-world evidence are decisive in differentiating competitive positioning, as payers and providers increasingly demand robust performance data and clear value propositions for new diagnostics. As competition intensifies, companies that can demonstrate interoperability, clinical utility, and operational support across diverse care settings will be best placed to capture long-term clinical and commercial relevance.

Actionable recommendations for industry leaders to accelerate adoption, manage risk, and align offerings with healthcare priorities

Industry leaders should prioritize a portfolio approach that balances investments in high-impact instruments with scalable consumable solutions that enable broad reach. By emphasizing modular product architectures and flexible service agreements, manufacturers can reduce procurement friction for hospitals and ambulatory surgical centers while enabling diagnostics laboratories to streamline throughput. In parallel, targeted clinical evidence generation focused on patient outcomes, cost-effectiveness, and real-world utility will strengthen negotiations with payers and support guideline inclusion. Establishing early and sustained dialogue with reimbursement authorities and health technology assessment bodies will also expedite pathways to coverage and adoption.

To mitigate trade and supply risks, organizations should diversify supplier bases and consider regional manufacturing or assembly hubs that reduce exposure to tariff volatility. Engaging in strategic partnerships with local distributors and research centers can accelerate market entry and ensure cultural alignment in outreach campaigns. Operationally, investing in digital platforms that facilitate patient reminders, remote specimen tracking, and seamless laboratory reporting will enhance adherence rates and clinician satisfaction. Finally, companies should cultivate clinician champions and collaborative pilot programs that demonstrate workflow integration, patient acceptability, and downstream clinical benefits. Together, these actions will create a resilient, evidence-backed approach to expanding the adoption of effective colorectal cancer screening and diagnostic solutions.

Research methodology outlining the evidence synthesis, primary engagement, and validation approaches used to develop the insights

The analysis synthesizes evidence from a structured mixed-methods approach combining primary qualitative engagement with clinical experts, laboratory directors, and procurement leaders alongside systematic review of peer-reviewed clinical literature and public regulatory documents. Primary research included in-depth interviews to capture operational constraints, procurement behaviors, and clinical preferences across hospitals, ambulatory surgical centers, diagnostics laboratories, and research institutes. Secondary sources were used to contextualize clinical guidelines, technological trajectories, and regulatory environments, ensuring interpretation of trends aligned with contemporary practice.

Data triangulation techniques were applied to reconcile findings from diverse information streams, and iterative validation with domain experts refined thematic conclusions and recommendations. The segmentation framework was mapped against modality characteristics, product types, clinical applications, and end-user workflows to produce actionable insights tailored to decision-making contexts. Limitations were acknowledged where data heterogeneity or regional variance reduced comparability, and sensitivity checks were conducted to ensure that conclusions reflect robust directional trends rather than single-source signals. Quality assurance procedures included expert review cycles and cross-validation of clinical claims against authoritative guideline statements to preserve factual accuracy and relevance for stakeholders.

Conclusion summarizing strategic implications and the priorities that will define the next phase of screening and diagnostic evolution

The colorectal cancer screening and diagnostics landscape is transitioning toward more patient-centric, evidence-driven, and operationally integrated models of care. Noninvasive modalities and consumable-centric offerings are expanding access and alleviating capacity constraints, while imaging and endoscopic platforms continue to offer definitive diagnostic and therapeutic capabilities. Trade policy and procurement dynamics add another layer of strategic complexity, underscoring the importance of supply chain resilience and localized approaches to manufacturing and distribution.

For stakeholders across the value chain, success will hinge on the ability to demonstrate clinical utility, operational value, and alignment with reimbursement priorities. Companies that build interoperable solutions, invest in rigorous clinical and real-world evidence, and cultivate collaborative partnerships with providers and payers will secure enduring advantage. At the same time, health systems that adopt organized screening programs, leverage digital engagement, and optimize procedural capacity can improve participation rates and downstream outcomes. The coming phase will reward those who couple technical innovation with pragmatic execution, ensuring that advances in diagnostics translate into measurable improvements in population health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence algorithms into colonoscopy imaging to improve real-time polyp detection sensitivity
  • 5.2. Clinical adoption of liquid biopsy assays for non-invasive detection and monitoring of colorectal cancer recurrence
  • 5.3. Rising market penetration of multi-target stool DNA tests as a screening alternative for average-risk populations
  • 5.4. Expansion of personalized screening protocols leveraging genetic risk profiling and novel biomarker panels
  • 5.5. Development of portable point-of-care colorectal screening devices for decentralized low-resource applications
  • 5.6. Deployment of telehealth-based patient engagement platforms for remote colorectal screening navigation and follow-up
  • 5.7. Shifts in reimbursement frameworks expanding coverage of non-invasive colorectal screening tests in public health systems
  • 5.8. Strategic partnerships between diagnostic laboratories and digital health firms to integrate colorectal cancer patient data

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Colorectal Cancer Screening & Diagnostic Market, by Type

  • 8.1. Screening Tests
    • 8.1.1. Blood Tests
    • 8.1.2. Imaging Tests
      • 8.1.2.1. Colonoscopy
      • 8.1.2.2. CT Colonography
      • 8.1.2.3. Flexible Sigmoidoscopy
  • 8.2. Stool Tests
    • 8.2.1. Fecal Immunochemical Test
    • 8.2.2. Guaiac-Based Fecal Occult Blood Test
    • 8.2.3. Multitarget Stool DNA Testing

9. Colorectal Cancer Screening & Diagnostic Market, by Product

  • 9.1. Consumables
    • 9.1.1. Kits
    • 9.1.2. Reagents
  • 9.2. Instruments
    • 9.2.1. CT Scanners
    • 9.2.2. Endoscopes

10. Colorectal Cancer Screening & Diagnostic Market, by Application

  • 10.1. Disease Monitoring
  • 10.2. Early Detection
  • 10.3. Prognosis Assessment

11. Colorectal Cancer Screening & Diagnostic Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostics Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Colorectal Cancer Screening & Diagnostic Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Colorectal Cancer Screening & Diagnostic Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Colorectal Cancer Screening & Diagnostic Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Abbott Laboratories
    • 15.3.2. AbbVie Inc.
    • 15.3.3. Agilent Technologies, Inc.
    • 15.3.4. Bayer AG
    • 15.3.5. Becton, Dickinson and Company
    • 15.3.6. Bio-Rad Laboratories, Inc.
    • 15.3.7. bioMerieux SA
    • 15.3.8. Bristol-Myers Squibb Company
    • 15.3.9. Clinical Genomics Technologies Pty Ltd.
    • 15.3.10. Eiken Chemical Co., Ltd.
    • 15.3.11. Epigenomics AG
    • 15.3.12. Exact Sciences Corp.
    • 15.3.13. F. Hoffmann-La Roche Ltd.
    • 15.3.14. Fujifilm Holdings Corporation
    • 15.3.15. GE HealthCare Technologies, Inc.
    • 15.3.16. Guardant Health, Inc.
    • 15.3.17. Hologic, Inc.
    • 15.3.18. Illumina, Inc.
    • 15.3.19. KARL STORZ SE & Co. KG
    • 15.3.20. Medtronic PLC
    • 15.3.21. Merck KGaA
    • 15.3.22. Myriad Genetics, Inc.
    • 15.3.23. Novartis AG
    • 15.3.24. Novigenix SA
    • 15.3.25. Olympus Corporation
    • 15.3.26. Prenetics Global Limited
    • 15.3.27. QIAGEN N.V.
    • 15.3.28. Quest Diagnostics Incorporated
    • 15.3.29. Sanofi SA
    • 15.3.30. Siemens AG
    • 15.3.31. Sysmex Corporation
    • 15.3.32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGI